The STW Take-Off program has just closed their 5th round. STENTiT is very pleased to announce that its Take-Off Phase II application has been granted. The funding will be used to expand the R&D lines, proceed with translational studies and further grow the business.
With this achievement we conclude 2016 which has been a very fruitful year for STENTiT.
We want to thank everyone that has supported us, and are really looking forward to further proceed next year regenerating diseased arteries without performing invasive surgery.